인쇄하기
취소

GOODTCELLS succeeds in attracting KRW 5 billion from Yuhan Corporation

Published: 2018-07-26 13:01:53
Updated: 2018-07-26 13:06:56

GOODTCELLS, a biopharmaceutical venture specializing in immune disorder therapies, announced on the 23rd that the company succeeded in attracting a KRW 5 billion investment from Yuhan Corporation(CEO Jung-Hee Lee).

Yuhan Corporation will keep 6.25% of the company share by investing KRW 5 billion into convertible stocks and will jointly develop new immune disorder therapies.

GOODTCELLS was fou...

Fees

- Email service daily and homepage access.
  1. $300 per month.
  2. 5 Email holders per each company.
  3. Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.